Aspire BioPharma, Inc. (ASBP)vsDoorDash, Inc. Class A Common Stock (DASH)
ASBP
Aspire BioPharma, Inc.
$8.88
+5.21%
CONSUMER CYCLICAL · Cap: $11.80M
DASH
DoorDash, Inc. Class A Common Stock
$169.49
-0.63%
CONSUMER CYCLICAL · Cap: $81.96B
Smart Verdict
WallStSmart Research — data-driven comparison
DoorDash, Inc. Class A Common Stock generates 16271659% more annual revenue ($15.89B vs $97,660). DASH leads profitability with a 5.3% profit margin vs 0.0%. DASH earns a higher WallStSmart Score of 48/100 (D+).
ASBP
Avoid22
out of 100
Grade: F
DASH
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ASBP.
Margin of Safety
+6.4%
Fair Value
$187.44
Current Price
$169.49
$17.95 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 35.6% year-over-year
Large-cap with strong market position
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
5.3% margin — thin
Operating margin of 3.9%
Weak financial health signals
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ASBP
The strongest argument for ASBP centers on Price/Book.
Bull Case : DASH
The strongest argument for DASH centers on Revenue Growth, Market Cap. Revenue growth of 35.6% demonstrates continued momentum. PEG of 1.05 suggests the stock is reasonably priced for its growth.
Bear Case : ASBP
The primary concerns for ASBP are Revenue Growth, EPS Growth, Market Cap.
Bear Case : DASH
The primary concerns for DASH are Profit Margin, Operating Margin, Piotroski F-Score. A P/E of 99.5x leaves little room for execution misses.
Key Dynamics to Monitor
ASBP profiles as a value stock while DASH is a hypergrowth play — different risk/reward profiles.
DASH carries more volatility with a beta of 1.89 — expect wider price swings.
DASH is growing revenue faster at 35.6% — sustainability is the question.
DASH generates stronger free cash flow (888M), providing more financial flexibility.
Bottom Line
DASH scores higher overall (48/100 vs 22/100) and 35.6% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aspire BioPharma, Inc.
CONSUMER CYCLICAL · AUTO PARTS · USA
Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company is headquartered in Humacao, Puerto Rico.
Visit Website →DoorDash, Inc. Class A Common Stock
CONSUMER CYCLICAL · INTERNET RETAIL · USA
DoorDash, Inc. operates a logistics platform that connects merchants, consumers, and merchants in the United States and internationally. The company is headquartered in San Francisco, California.
Visit Website →Compare with Other AUTO PARTS Stocks
Want to dig deeper into these stocks?